Meeting
2023 ASCO Annual Meeting
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Authors
Sagar Lonial
Winship Cancer Center of Emory University, Atlanta, GA
Sagar Lonial , HANG QUACH , Meletios A. Dimopoulos , Paula Rodríguez-Otero , Jesus G. Berdeja , Paul G. Richardson , Margee Kyada , Shuyu Chu , Min Chen , Patricia C. Abad , Juliane Morando , Niels W.C.J. van de Donk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04975997
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8069)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8069
Abstract #
TPS8069
Poster Bd #
58a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
First Author: Paul G. Richardson
Poster
2021 ASCO Annual Meeting
LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).
First Author: Maria-Victoria Mateos
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess